Gepotidacin is a novel first-in-class triazaacenaphthylene bacterial topoisomerase inhibitor designed to treat bacterial infections, including those caused by multidrug-resistant pathogens. By inhibiting… Read more
Gepotidacin is a novel first-in-class triazaacenaphthylene bacterial topoisomerase inhibitor designed to treat bacterial infections, including those caused by multidrug-resistant pathogens. By inhibiting DNA gyrase and topoisomerase IV, this agent effectively halts bacterial DNA replication. This category provides access to high-quality Gepotidacin reference standards, including the mesylate form and associated impurities, which are essential for rigorous analytical testing and method development. Pharmaceutical laboratories rely on these materials for impurity profiling, qualification of unknown degradation products, and method validation during drug development and quality control processes. By utilizing these characterized reference standards, researchers can ensure the accuracy of assays, confirm compound identity, and maintain strict adherence to regulatory standards for drug safety and consistency. These materials support the comprehensive analysis required to verify the chemical integrity of formulations throughout the product lifecycle.